2018 NVC Phase II Teams Announced

The Polsky Center is thrilled to announce the 30 teams advancing to the semifinals of the 2018 Edward L. Kaplan, ’71, New Venture Challenge (NVC). The NVC is the University of Chicago’s nationally ranked accelerator program that has graduated more than 180 startup companies still in operation today.

Teams advancing to the Phase II portion of the accelerator program will work to launch their ideas into viable businessess and perfect their business plan and pitch. The teams are:

Abeona is a lightweight, affordable bear-resistant food container.

Almondaire produces the first vegan almond cream style liqueur in the US market.

Bevy provides an online renting platform for equipment intended to help people do more activities while owning less.

BrewBike is the world’s best way to get quality, convenient cold brew on the go.

Builtti is the first home improvement solution platform designed to be a trusted one stop shop for finding contractors and buying home improvement supplies in Latin America.

Coeus.ai uses deep learning to analyze video-game recordings to allow pro-gamers and game-streamers to create instant highlights.

Commix is a technology consulting company with the focus on creating Data Integration solutions.

Conduit Labs is building a hardware-independent software tools platform for Internet of Things developers.

D20 Robotics produces robots in the alcohol service and entertainment industries.

ForeseeABill is an informatics solution for use in clinical trials.

Fulbito provides an intuitive platform to serve as a marketplace for the supply and demand-side of the amateur athletic space.

Ganbei, LLC seeks to disrupt the American liquor market with carefully selected spirits that have deep roots, long traditions, and exceptional qualities from around the world.

Good Noggin is an FDA-approved, medical scanning technology for mobile devices that screens and monitors treatment of infants with Flat Head Syndrome.

GrannyNanny is an application dedicated to connecting non-medical caregivers with families seeking assistance to help a care recipient who is 65+.

HayStack ABI is making advanced analytics available to growing businesses that don’t have sufficient technical expertise, money, and/or time.

ImmunArtes is developing a vaccine to address the urgent and unmet need of preventing Staph infection.

LiveBeat develops wearable devices and apps to reliably monitor fetal heartrate and movements outside the hospitals.

Locale Vine is an online meal selection, grocery shopping, and delivery platform aimed at reducing food waste.

Oxalo Therapeutics is developing a first-in-class drug to prevent recurrent kidney stones.

Manifest will make 401(k) transfers seamless for employees and retirement providers.

MindFull is a high protein, low carb ice cream sandwich which makes a person feel full without guilt and without the experience of a sugar crash.

Muu is a delicious Brazilian ice cream that has less calories, more protein and less fat than traditional brands.

nuBorn Medical is developing the OroScope, a non-invasive assessment device that enables clinicians to objectively diagnose preterm infant feeding deficits.

O2Fund helps large corporations in Brazil seamlessly organize, manage and scale early payment programs to their supplier base.

Pangea Medical aims to lower hospital readmission rates by providing care coordination and in-home nurse visits during the critical 30-day post-discharge period.

PROMISS Diagnostics develops diagnostic solutions to assist physicians in improving women’s health outcomes.

Rudolph Data builds software-enabled solutions to aggregate and validate cutting edge commercial real estate data.

Seedling is a financial services platform connecting the un and underbanked with banks and retailers by redirecting existing gambling behaviors towards savings behaviors.

SensientHR is a multi-stakeholder tool that helps small to mid-sized enterprises retain their valuable professionals.

Seurat Therapeutics’ mission is to develop a novel therapeutic to treat frequent migraine attacks using a targeted nose-to-brain formulation.